Under New Name, Ocata Positioned as R&D Hub for Regenerative Medicine, Ophthalmology: Astellas

May 12, 2016
Astellas President Yoshihiko Hatanaka Astellas Pharma President Yoshihiko Hatanaka said on May 11 that US cell therapy firm Ocata Therapeutics, the company acquired earlier this year, now bears a new name and will be positioned as Astellas’s R&D hub for...read more